TSLA
Tesla
-- 288.140 NVDA
NVIDIA
-- 120.690 PLTR
Palantir
-- 96.500 TNON
Tenon Medical
-- 3.750 GME
GameStop
-- 25.400 
Sunday NEWS
Longeveron Said ELPIS I Met Its Primary Endpoint Of Safety Through 1-year Post-treatment, With 100% Survival Rate
10/27/2024 - 12:10 PM
▪️Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none requiring heart transplant; this compared to the largest data set from the Single Ventricle Reconstruction Trial which showed 83% survival, with a 5.2%heart transplantation rate
▪️ELPIS I met its primary endpoint of safety through 1-year post-treatment, with 100%survival rate, 100% transplant-free and patients maintained expected rate of growth one year after treatment
▪️Findings support cell based therapy as a potential adjunct to HLHS reconstruction surgery to improve clinical benefits and reduce the need for subsequent heart transplantation
▪️ELPIS II Phase 2b clinical trial is currently ongoing, further evaluating Lomecel-BTM as a potential adjunct therapy for HLHS versus standard of care alone
▪️Oral presentation highlights findings that patients treated with Lomecel-BTM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none requiring heart transplant; this compared to the largest data set from the Single Ventricle Reconstruction Trial which showed 83% survival, with a 5.2%heart transplantation rate
▪️ELPIS I met its primary endpoint of safety through 1-year post-treatment, with 100%survival rate, 100% transplant-free and patients maintained expected rate of growth one year after treatment
▪️Findings support cell based therapy as a potential adjunct to HLHS reconstruction surgery to improve clinical benefits and reduce the need for subsequent heart transplantation
▪️ELPIS II Phase 2b clinical trial is currently ongoing, further evaluating Lomecel-BTM as a potential adjunct therapy for HLHS versus standard of care alone
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment